This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Abstract Core Conclusions: The AR competitive landscape is dominated by three approved next-generation AR antagonists — Enzalutamide (Pfizer/Astellas), Apalutamide (Janssen), and Darolutamide (Bayer/Orion) — which collectively cover all prostate cancer disease settings from non-metastatic CRPC to metastatic hormone-sensitive disease. The frontier of competition has shifted toward (1) AR degraders that overcome AR splice variant (AR-V7)-driven resistance, (2) combination strategies pairing AR antagonists with PARP inhibitors or other agents, and (3) non-oncology AR applications in…
Author: Eureka LS
This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Abstract Core Conclusions: BTK is a validated, high-value target with 12 approved drugs across oncology and autoimmune disease as of 2026. The competitive arena has three active fronts: (1) a mature B-cell malignancy segment where BeOne Medicines’ zanubrutinib has clinically outperformed ibrutinib and is now the dominant second-generation covalent BTK inhibitor globally; (2) a rapidly growing autoimmune/neuroinflammation segment where Novartis (remibrutinib), Sanofi (tolebrutinib, rilzabrutinib) achieved approvals in 2025; and (3) an emerging BTK degrader/PROTAC…
This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Abstract Core Conclusions: Traditionally, compiling this level of analysis would require weeks of manual research across platforms like Google Patents and PubMed. With Eureka LS, the same process can be automated—from extracting molecules to mapping competitive pipelines—into a structured output like the report below. Section I: Target Biology & Epidemiological Context i. KRAS G12D — Molecular Profile KRAS (Kirsten RAS proto-oncogene, GTPase; UniProt P01116; HGNC 6407) encodes a small GTPase that cycles between…
This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary CLDN18.2 has matured from a single-asset target (zolbetuximab) into one of the most densely contested oncology spaces globally. The database records 262 drug assets, 199 clinical trials, and 145 clinical result readouts. The dominant modality has shifted decisively to ADCs (>50% of clinical assets), with bispecifics and CAR-T emerging as the next wave. The competitive arena is overwhelmingly China-driven: roughly 85% of all assets originate from Chinese biotech/pharma, while Western majors participate primarily through…
This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Abstract Core Conclusions: Type 2 Diabetes Mellitus (T2DM) is the world’s largest chronic disease market, with projected global patient populations exceeding 700 million by 2045. The competitive landscape has undergone a structural shift: GLP-1 receptor agonists and SGLT2 inhibitors have moved from adjunct therapies to preferred first-line agents due to proven cardiovascular and renal benefits. The frontier is now defined by multi-receptor agonists (GLP-1/GIP/GCGR), oral incretin formulations, and AI-powered drug discovery, with China emerging as…
This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary The PROTAC (PROteolysis TArgeting Chimera) sector has matured from academic curiosity to late-stage clinical reality in fewer than eight years. As of April 2026, at least 8 distinct PROTAC assets have reached Phase 2 or beyond, with vepdegestrant (ARV-471/Arvinas–Pfizer) already at NDA/BLA stage after a positive Phase 3 VERITAC-2 readout in ESR1-mutant ER+/HER2− breast cancer — the first PROTAC to reach this milestone globally. ir.arvinas.com The competitive arena is US-originator-led but globally partnered, with Big Pharma (Pfizer,…
This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary PAH is a progressive, rare, life-threatening disease (WHO Group 1 pulmonary hypertension) characterized by remodeling of the pulmonary arterioles, elevated pulmonary vascular resistance, and eventual right heart failure. The market has historically been segmented around three mechanistic pillars — prostacyclin pathway agonism, endothelin receptor antagonism (ERA), and nitric oxide/cGMP pathway enhancement (PDE5i / sGC stimulators) — all of which reduce pulmonary vascular tone but do not reverse vascular remodeling. The 2024 approval…
This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary The CAR-T field has matured from a single-product niche into a $5B+ commercial market with 10 approved products across two antigen classes (CD19 and BCMA). Gilead/Kite and Bristol Myers Squibb dominate with multiple approved products each, while Legend Biotech/Janssen’s CARVYKTI has emerged as the best-in-class BCMA therapy by efficacy metrics. Three structural shifts define the current competitive dynamics: (1) the frontier is moving from late-line to earlier lines of therapy, expanding addressable populations; (2) allogeneic (“off-the-shelf”) CAR-T…
This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary The BTK inhibitor class is one of the most competitive targeted therapy spaces in oncology, anchored by Ibrutinib (Imbruvica®) as the first-in-class approved agent since 2013 but increasingly challenged by improved second-generation covalent inhibitors and a pioneering non-covalent third generation. The database identifies 385 BTK-targeting drugs globally, with 9 having achieved regulatory approval across hematologic malignancies and, more recently, autoimmune/neurological indications. The competitive dynamics are bifurcated: in B-cell malignancies, Zanubrutinib (BeOne Medicines)…
This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Abstract Nivolumab (Opdivo®) is a fully human IgG4 anti-PD-1 monoclonal antibody co-originated by Bristol Myers Squibb (BMS) and Ono Pharmaceutical, first approved in July 2014. It is the first anti-PD-1 drug to reach regulatory approval globally and has grown into one of the broadest-label immuno-oncology agents in the world, spanning 473 researched disease indications. The PD-1/PD-L1 checkpoint inhibitor class is now highly crowded, with 22 approved PD-1 agents and 12 approved PD-L1 agents globally. Nivolumab’s primary global competitor is Pembrolizumab (Keytruda®,…